Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04752358
Status:
TERMINATED
Last Update Posted:
2024-05-09
First Post:
2021-02-08
Brief Title:
ADP-A2M4CD8 in HLA-A2 Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers SURPASS-2
Sponsor:
Adaptimmune
Organization:
Adaptimmune
Study Overview
Official Title:
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
Status:
TERMINATED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was terminated due to difficulty recruiting subjects and lack of efficacy
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen HLA and tumor antigen status and whose esophageal or esophagogastric junction EGJ cancer expresses the MAGE-A4 protein
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None